Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
FKTN encodes the golgi-resident glycosyltransferase fukutin required for α-dystroglycan maturation. A single non-Japanese patient with late-onset LGMD2M presented at age 14 with rigid spine syndrome, limb-girdle weakness and cardiomyopathy, carrying a homozygous c.917A>G (p.Tyr306Cys) variant inherited from carrier parents, confirming FKTN’s role in LGMD2M (PMID:23746544).
In vitro studies demonstrate that wild-type fukutin localizes to the medial-Golgi, whereas pathogenic missense mutants mislocalize to the endoplasmic reticulum, leading to hypoglycosylation of α-dystroglycan; low-temperature and chemical chaperone treatments can restore localization and glycosylation (PMID:12471058; PMID:22275357). This supports a loss-of-function mechanism amenable to folding-amelioration therapies. Key take-home: FKTN variant analysis is essential for diagnosing LGMD2M and exploring targeted interventions.
Gene–Disease AssociationLimitedSingle unrelated proband with homozygous variant; carrier parents segregation; confirmed by functional data Genetic EvidenceLimited1 proband with homozygous c.917A>G (p.Tyr306Cys) in AR inheritance ([PMID:23746544]) Functional EvidenceModerateIn vitro studies show Golgi localization of wild-type fukutin and ER mislocalization of pathogenic mutants causing hypoglycosylation; rescue by chaperone approaches ([PMID:12471058]; [PMID:22275357]) |